The DEA intends to temporarily classify 7-OH, an opioid-like compound from kratom, as a Schedule I controlled substance, impacting its availability in the market.
New Delhi, India Jul 3, 2026 ALN: The Drug Enforcement Administration (DEA) has announced plans to temporarily ban 7-OH, a compound derived from kratom that exhibits opioid-like effects. This compound is increasingly available in various forms, including gummies, drinks, and capsules, sold at gas stations and smoke shops across the United States. The DEA's decision is significant, as it aims to classify 7-OH as a Schedule I substance under the Controlled Substances Act, placing it in the same category as heroin, which is reserved for drugs deemed to have a high potential for abuse and no accepted medical use.
The proposed ban is set to take effect for a period of two years, with the possibility of extending it for an additional third year. The DEA has expressed concern that 7-OH poses severe risks to public health, including the potential for tolerance, dependence, and addiction. This action reflects ongoing debates about the safety and regulation of kratom and its derivatives.
Kratom, scientifically known as Mitragyna speciosa, is a tropical evergreen tree native to Southeast Asia. Traditionally, it has been used in herbal medicine for its analgesic (pain-relieving) and antidepressant properties, especially when consumed in low doses. However, the natural form of kratom contains only trace amounts of 7-OH, and the recent surge in the production and sale of unregulated 7-OH products has raised alarms among health officials and regulatory bodies.
In May, former President Donald Trump expressed support for "natural 7-OH," indicating a potential interest in exploring its approval. This endorsement has been significant for the kratom industry, which has been advocating for the benefits of kratom while simultaneously pushing back against the negative perceptions associated with its synthetic derivatives.
The involvement of high-profile government officials in the kratom industry has further complicated the regulatory landscape. Health and Human Services Secretary Robert F. Kennedy Jr. and Department of Homeland Security Secretary Markwayne Mullin have both been linked to the kratom sector, with Kennedy photographed alongside JW Ross, the founder of Botanic Tonics, a company that produces kratom-infused beverages. This connection has raised ethical questions, particularly given that Botanic Tonics was subjected to a federal raid in 2023 due to concerns over the safety and regulation of its products.
During the raid, the Food and Drug Administration (FDA) noted that there was insufficient information on whether kratom, marketed as a dietary supplement, posed a significant or unreasonable risk of illness or injury. The Department of Justice later dropped its case against Botanic Tonics, and financial contributions from an LLC associated with the company to a political action committee have drawn scrutiny, suggesting potential conflicts of interest among government officials.
Consumer experiences with kratom and its derivatives are varied, with some users reporting adverse effects. Many consumers of Feel Free, a brand associated with Botanic Tonics, have claimed to experience severe withdrawal symptoms linked to their use of the product. This highlights the complexities surrounding the use of kratom and its derivatives, as well as the need for more comprehensive research into their safety and efficacy.
The DEA's proposed ban on 7-OH has been met with mixed reactions. Proponents of regulation, including lobbyists from the kratom industry, view this action as a necessary step to distinguish between natural kratom and its synthetic counterparts. Mac Haddow, a senior fellow on public policy for the American Kratom Association, stated that the action should clarify the debate surrounding the safety of kratom products. He emphasized that chemically manipulated 7-OH compounds are not representative of natural kratom and pose a public health threat that responsible regulators must address.
Conversely, advocates for 7-OH argue that the proposed ban lacks a scientific foundation. Jeff Smith, executive director of the Holistic Alternative Recovery Trust, a group that supports 7-OH, expressed concerns about the potential impact on consumers who have found relief through its use. He noted that many individuals have reported significant improvements in their quality of life, enabling them to manage pain and return to work. The impending ban could disrupt the lives of these consumers, leading them to seek out alternative, potentially more dangerous substances.
One user of 7-OH, who wished to remain anonymous due to concerns about professional repercussions, shared her experience with the compound. She stated that using 7-OH has allowed her to discontinue other opioids, including illicit drugs, and expressed her apprehension about the potential consequences of a ban. "I don’t want to go back to that," she said, reflecting the fear many users may have regarding the loss of a substance that has provided them with a measure of control over their pain and addiction.
The DEA's announcement also included plans to take action against other derivatives of 7-OH and synthetic opioids, underscoring the ongoing challenges of regulating synthetic drugs. The rise of synthetic substances often leads to a game of "whack-a-mole" for regulators, as new compounds emerge in the market faster than they can be controlled. This dynamic makes it increasingly difficult to ensure public safety while balancing the needs of consumers seeking alternative treatments.
The proposed ban on 7-OH will enter a public comment period lasting 30 days, during which stakeholders, consumers, and the general public will have the opportunity to voice their opinions and concerns regarding the regulation of this compound. As the conversation surrounding kratom and its derivatives continues, the implications of this ban will likely reverberate throughout the industry and among consumers who rely on these products for pain management and quality of life.
In conclusion, the DEA's plans to temporarily ban 7-OH represent a significant development in the ongoing debate over the regulation of kratom and its derivatives. While supporters of the ban argue that it is a necessary measure to protect public health, critics contend that it may further marginalize individuals who have found relief through these substances. The outcome of the public comment period and subsequent regulatory decisions will shape the future of kratom and its derivatives in the United States.
To learn more about the latest developments in Healthcare Innovations, stay updated with our exclusive reports and analyses on AiLensNews.
